CYNATA - 2021 The Year of Multiple Trials

I think we need to focus more on the operations of CYP here, the key drivers in trials

1. OA phase 3, the pilot trial should now be complete and being assessed with the remainder of recruitment to take place throughout Q1. I however expect trial results to come much sooner for many of the trials below
2. GvHD managed by Fuji, do we know when trials restarting in Japan - phase 2
3. MEND for non-covid ARDS - phase 2
4. MEND for non-covid Sepsis - phase 2
5. MEND for non-covid CRS - phase 2 - is Rasko managing this, he recently stated on his website that he was (in addition to a number of other trials) but then altered that when investors started asking him questions
6. CLI approved - phase 2
7. idiopathic pulmonary fibrosis (IPF) - phase 2
8. renal transplantation - phase 2
9. diabetic foot ulcers (DFU) - phase 2

Wondering which hospitals/countries these trials are planned for. Rasko stated on his website that he'd be going ahead with a few of them. Wondering whether any of our other pre-clinical investigators will be involved. Would love to see King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Saudi Arabia again involved (KFSH&RC runs the largest organ transplantation program in the Middle East, performing approximately 1,500 transplants in 2017, a figure that is comparable to the largest transplantation centres globally).

MSB has it's own problems, FDA pointed out significant manufacturing issues that will be very challenging and expensive to resolve, if ever resolved, huge cash burn that they've said will need to be managed by products stemming from successful phase 3s and then shortly after the three recent phase 3s that have been unsuccessful.
I think there's enough for MSBers to focus on with their own stock, that involve issues independent of us, without us and them having to compare the two companies constantly. I see CYP on it's own path quite independent of MSB. From a market liquidity perspective I do believe we have many common investors so significant falls in MSB require some of our holders to offload but operationally we need to focus on our own trials moving forward.

@elvisj

thanks to Elvis

A thread to track and discuss our multiple approved and upcoming trials.